drugset

drugset / Trial / NCT00299832

SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction

NCT00299832 ↗

Phase 3 Completed 40 enrolled Novartis

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Assessing the safety, efficacy and pharmacokinetics of SPP100 (Aliskiren) regimen in hypertensive patients with renal dysfunction

Timeline

Start: 2006-04
Primary completion: 2007-05
Completion: 2007-05

Publications

Results Ito S, Nakura N, Le Breton S, Keefe D. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res. 2010 Jan;33(1):62-6. doi: 10.1038/hr.2009.175. Epub 2009 Nov 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aliskiren	Small molecule	300 mg	Oral

Indications